Loading
A phase 1/2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT05067140 by Novartis Pharmaceuticals, with 164 participants enrolled, started 2021-09-02 and due to reach its primary completion in 2027-05-25. Interventions recorded: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT). Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.